Clinicopathologic factors predicting complete pathological response to neoadjuvant chemoradiotherapy in esophageal cancer

Diseases of the Esophagus

Volumn 19, Issue 4, 2006, Pages 273-276

  MacGuill, M ^a   Mulligan, E ^a   Ravi, N ^a   Rowley, S ^a   Byrne, P J ^a   Hollywood, D ^a   Kennedy, J ^a   Keeling, P N ^a   Reynolds, John V ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Chemoradiotherapy; Esophageal cancer; Multimodal therapy

Indexed keywords

ALCOHOL; ANTINEOPLASTIC AGENT;

ADENOCARCINOMA; ADULT; AGE; AGED; ANAMNESIS; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHI SQUARE TEST; CLINICAL FEATURE; CONTROLLED STUDY; DATA BASE; DISEASE DURATION; ESOPHAGUS CANCER; FEMALE; GENDER; HISTOPATHOLOGY; HUMAN; IRELAND; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; TOBACCO; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33745871928     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2006.00576.x     Document Type: Article

References (26)

1. Enzinger P C, Mayer R J. Esophageal Cancer. N Engl J Med 2003; 349: 2241-52.
2. Fiorica F, Di Bona D, Schepis F et al. Preoperative chemoradiotherapy for oesophageal cancer: A systematic review and meta-analysis. Gut 2004; 53: 925-30.
3. Urschel J D, Vasan H. A meta-analysis of randomised controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003; 185: 538-43.
4. Walsh T N, Noonan N, Hollywood D et al. A comparison of multimodal therapy and surgery for oesophageal adenocarcinoma. N Engl J Med 1996; 335: 462-7.
5. Kelsen D. Preoperative chemoradiotherapy for esophageal cancer. J Clin Oncol 2001; 19: 283-5.
6. Geh J I, Crellin A M, Glynne-Jones R. Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg 2001; 88: 338-56.
7. Bosset J F, Gignoux M, Triboulet J P et al. Chemotherapy followed by surgery compared with surgery alone in squamous cell cancer of the esophagus. N Engl J Med 1997; 337: 161-7.
8. Mandard A M, Dalibard F, Mandard J C et al. Pathologic assessment of tumour regression after preoperative chemoradiotherapy of oesophageal carcinoma. Cancer 1994; 73: 2680-6.
9. Dunne B, Reynolds J V, Mulligan E, Kelly A, Griffin M. A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy. J Clin Pathol 2001; 54: 841-5.
10. Shackney S E, McCormack G W, Cuchural G et al. Growth rate patterns of solid tumours and their relation to responsiveness to therapy. Ann Intern Med 1978; 89: 107-21.
11. Eloubeidi M A, Desmond R, Arguedas M R, Reed C E, Wilcox C M. Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: The importance of tumor length and lymph node status. Cancer 2002; 95: 1434-43.
12. Fisher B, Anderson S, Wickerham D L et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from the National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997; 15: 1858-69.
13. Stradmauer E A, O'Neill A, Goldstein L J et al. Conventional dose chemotherapy compared with high-dose chemotherapy plus autologous haematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med 2000; 342: 1069-76.
14. Verheik M, Batelink H. Radiation-induced apoptosis. Cell Tissue Res 2000; 301: 133-42.
15. Hickman J A. Apoptosis induced by anticancer drugs. Can Metastasis Rev 1992; 11: 121-39.
16. Raouf A, Evoy D, Carton E et al. Spontaneous and inducible apoptosis in oesophageal adenocarcinoma. Br J Cancer 2001; 85: 1781-6.
17. Attardi L D, Jacks T. The role of p53 in tumour suppression: Lessons from mouse models. Cell Mol Life Sci 1999; 55: 48-63.
18. Wallace-Brodeur R R, Lowe S W. Clinical implications of p53 mutations. Cell Mole Life Sci 1999; 55: 64-75.
19. Raouf A, Evoy D A, Carton E et al. Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumour progression and worse survival but not with response to neoadjuvant chemoradiation. Dis Esophagus 2003; 16: 17-23.
20. Abdel-Laetif M M, O'Riordan J, Windle H J et al. Ann Surg 2004; 239: 491-500.
21. Petricoin E F, Ardekani A M, Hitt B A et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572-9.
22. Chang J C, Wooten E C, Tsimelzon A et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003: 362-9.
23. Johnstone R W, Ruefli A A, Lowe S W. Apoptosis: A link between cancer genetics and chemotherapy. Cell 2002; 108: 153-64.
24. Brucher B L et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: Response evaluation by positron emission tomography. Ann Surg 2001; 233: 300-9.
25. Downey R J et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: Results of a prospective trial. J Clin Oncol 2003; 21: 428-32.
26. Habr-Gama A, Perez R O, Nadalin W et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy. Ann Surg 2004; 240: 711-18.